- Home
- DBRG vs TVTX Comparison
DBRG vs TVTX Comparison
Compare DBRG & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- TVTX
- Stock Information
- Founded
- DBRG 1991
- TVTX 2008
- Country
- DBRG United States
- TVTX United States
- Employees
- DBRG N/A
- TVTX N/A
- Industry
- DBRG Real Estate Investment Trusts
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- TVTX Health Care
- Exchange
- DBRG Nasdaq
- TVTX Nasdaq
- Market Cap
- DBRG 1.8B
- TVTX 1.5B
- IPO Year
- DBRG 2009
- TVTX N/A
- Fundamental
- Price
- DBRG $11.79
- TVTX $23.65
- Analyst Decision
- DBRG Strong Buy
- TVTX Strong Buy
- Analyst Count
- DBRG 7
- TVTX 16
- Target Price
- DBRG $16.00
- TVTX $35.20
- AVG Volume (30 Days)
- DBRG 1.9M
- TVTX 2.7M
- Earning Date
- DBRG 10-31-2025
- TVTX 10-30-2025
- Dividend Yield
- DBRG 0.34%
- TVTX N/A
- EPS Growth
- DBRG N/A
- TVTX N/A
- EPS
- DBRG N/A
- TVTX N/A
- Revenue
- DBRG $173,540,000.00
- TVTX $333,865,000.00
- Revenue This Year
- DBRG N/A
- TVTX $83.26
- Revenue Next Year
- DBRG $77.07
- TVTX $43.19
- P/E Ratio
- DBRG N/A
- TVTX N/A
- Revenue Growth
- DBRG N/A
- TVTX 87.94
- 52 Week Low
- DBRG $6.41
- TVTX $12.91
- 52 Week High
- DBRG $17.33
- TVTX $28.69
- Technical
- Relative Strength Index (RSI)
- DBRG 57.87
- TVTX 63.45
- Support Level
- DBRG $11.13
- TVTX $22.52
- Resistance Level
- DBRG $12.58
- TVTX $28.69
- Average True Range (ATR)
- DBRG 0.37
- TVTX 1.53
- MACD
- DBRG 0.04
- TVTX 0.24
- Stochastic Oscillator
- DBRG 48.04
- TVTX 55.85
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.